In liver cells, two specific DNA switches work together to turn on a gene called PCSK9 — if you break one switch (HNF1), the other one (SRE) can’t do its job properly, even if it’s still intact.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes a specific molecular mechanism tested in a controlled in vitro system (HepG2 cells) using targeted mutagenesis — a standard approach in molecular biology to establish causal interactions between transcription factor binding sites and gene regulation. The use of 'significantly reduces' is appropriate because such experiments typically include statistical validation. The claim is precise, testable, and does not overgeneralize beyond the cell line or experimental context.
More Accurate Statement
“In HepG2 cells, mutation of the HNF1 binding site in the PCSK9 promoter significantly reduces SREBP2-dependent transcriptional activation of PCSK9, even when the SRE site is intact.”
Context Details
Domain
molecular_biology
Population
in_vitro
Subject
HNF1 and SRE sites in the PCSK9 promoter in HepG2 cells
Action
function cooperatively
Target
the ability of SREBP2 to activate PCSK9 transcription
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*
The study found that if you break the HNF1 part of the gene’s control switch, even the SREBP2 part can’t turn on the gene properly — proving they need to work together.